| Chapter title |
Immunotherapeutic approaches in pancreatic cancer.
|
|---|---|
| Chapter number | 18 |
| Book title |
Pancreatic Cancer
|
| Published in |
Recent results in cancer research Fortschritte der Krebsforschung Progrès dans les recherches sur le cancer, January 2008
|
| DOI | 10.1007/978-3-540-71279-4_18 |
| Pubmed ID | |
| Book ISBNs |
978-3-54-071266-4, 978-3-54-071279-4
|
| Authors |
Stieler, J, Jens Stieler, Stieler, Jens |
| Abstract |
With growing understanding of the regulation of immune responses, multiple new immunotherapeutic targets have evolved. This article gives a survey over the current approaches in pancreatic cancer therapy including peptide vaccinations, unspecific immunotherapy, allogene modified tumor cell vaccines, and vector-based vaccines. Although several trials have shown detectable immune responses, such as delayed-type hypersensitivity reactions and cytokine release in enzyme-linked immunosorbent spot (ELISPOTS) assays, and some have reported prolonged survival for immune responders, immunotherapy remains experimental. However, some approaches have made it into a phase III setting. In addition, the emerging concept of tumor stem cells may lead to a new focus on immunotherapy, since these often highly chemotherapy-resistant cells are thought to be the source of recurrences. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 10% |
| Unknown | 9 | 90% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 30% |
| Student > Ph. D. Student | 3 | 30% |
| Student > Bachelor | 1 | 10% |
| Student > Master | 1 | 10% |
| Student > Postgraduate | 1 | 10% |
| Other | 0 | 0% |
| Unknown | 1 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 3 | 30% |
| Biochemistry, Genetics and Molecular Biology | 2 | 20% |
| Agricultural and Biological Sciences | 2 | 20% |
| Engineering | 1 | 10% |
| Unknown | 2 | 20% |